Liposomal amphotericin B for leishmaniasis treatment of AIDS patients unresponsive to antimonium compounds.
Lazanas
M C
MC
Tsekes
G A
GA
Papandreou
S
S
Harhalakis
N
N
Scandali
A
A
Nikiforakis
E
E
Saroglou
G
G
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000328:Adult; D000666:Amphotericin B / Q000627:therapeutic use*; D004304:Dosage Forms; D005260:Female; D006801:Humans; D007898:Leishmaniasis, Visceral / Q000188:drug therapy*; D008081:Liposomes; D008297:Male; D008536:Meglumine / Q000627:therapeutic use*; D000077485:Meglumine Antimoniate; D008875:Middle Aged; D009942:Organometallic Compounds / Q000627:therapeutic use*
D004304:Dosage Forms; D008081:Liposomes; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate; D000666:Amphotericin B